As part of the dialogue with the pharmaceutical industry, the German government has promised to introduce the option of a confidential reimbursement amount. The aim is to support pharmaceutical companies whose products are subject to a considerable price decrease after undergoing an AMNOG benefit assessment by offering the option to keep the new price confidential.